Skip to content
Home
About Us
Longevity Platform
Bio101
BIO101 in Sarcopenia
BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
Posters & Publications
Scientific Press Releases
Recruitment
Investors
Stock Information
Corporate Presentation
Letter to shareholders
Press Releases
General Meetings
AMF Regulated Information
SEC Filings
Convertible bonds
Pre-financed vouchers (PFW)
Obligations Hexagon
Contact for Investors
Contact
EN
FR
Blog Category
April 7, 2020
Biophytis Launches COVA Clinical Study with Sarconeos (BIO101) in Covid-19
Press Releases
,
Scientific
/
7 April 2020
Biophytis Announces Launch of a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders
Financial
,
Press Releases
/
7 April 2020
Biophytis has signed a New Convertible Bond Financing of €24 million from Atlas to Continue the Development of Sarconeos (BIO101)
Financial
,
Press Releases
/
7 April 2020
Go to Top
Home
About Us
Longevity Platform
Bio101
BIO101 in Sarcopenia
BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
Posters & Publications
Scientific Press Releases
Recruitment
Investors
Stock Information
Corporate Presentation
Letter to shareholders
Press Releases
General Meetings
AMF Regulated Information
SEC Filings
Convertible bonds
Pre-financed vouchers (PFW)
Obligations Hexagon
Contact for Investors
Contact
EN
FR